CTMX
CytomX Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 16 ▼ CytomX Therapeutics announced a public offering of $250.0 million in…
- Mar 16 CytomX Therapeutics reported financial results for 2025, highlighted…
- Mar 16 Offering: CytomX Therapeutics Announces Proposed Public Offering of…
- Mar 17 ▼ 4 insiders sell $1.2M at $6.42
- Mar 18 CytomX Therapeutics priced a public offering of 45,990,567 shares an…
- Jun 3 Contract: CytomX Announces Expansion of Strategic Research Collabora…
- Jun 15 ▼ 1 insider sell $5.0K at $3.05
- Nov 5 ▼ Earnings: CTMX Q3 2026 Earnings: EPS $-0.09 (-1.5% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
4 insiders sold $1.2M.
- InstitutionsBULLISH
Q3 2026: 26 added (0 new), 7 trimmed or exited.
- AnalystsBULLISH
13 of 14 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.103 → −$0.082 over 90 days. 2 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest +5.7% to 45.25M shares. 12.0 days to cover, ≈20.8% of shares.
- TrendDOWNTREND
22% below its 50-day average. New closing low $1.98 on Nov 10.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MARSHALL WACE, LLP | ADD | $11.9M |
| Qube Research & Technologies Ltd | DOUBLED | $11.4M |
| Squarepoint Ops LLC | DOUBLED | $4.0M |
| Assenagon Asset Management S.A. | DOUBLED | $3.2M |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | $2.2M |
| Jump Financial, LLC | DOUBLED | $2.0M |
| DIMENSIONAL FUND ADVISORS LP | TRIM | $1.7M |
| BARCLAYS PLC | DOUBLED | $1.5M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
14 analystsPrice is below the lowest target. Median implies +505%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 12, 2026 | JP Morgan MAINTAIN | Overweight |
| Nov 6, 2026 | Wedbush MAINTAIN | Outperform |
| Aug 13, 2026 | JP Morgan MAINTAIN | Overweight |
| Aug 10, 2026 | Guggenheim MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Carvajal Alejandra Chief Legal Officer Aug 3, 2026 | AWARD | 450,000 sh |
Carvajal Alejandra Chief Legal Officer Aug 3, 2026 | AWARD | 100,000 sh |
Fuchs Charles S. Director Jul 24, 2026 | AWARD | 118,000 sh |
Ashworth Alan Director Jun 17, 2026 | AWARD | 59,000 sh |
Mohindru Mani Director Jun 17, 2026 | AWARD | 59,000 sh |
Jones Elaine V Director Jun 17, 2026 | AWARD | 59,000 sh |
Su Zhen Director Jun 17, 2026 | AWARD | 59,000 sh |
Young Matthew P. Director Jun 17, 2026 | AWARD | 59,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.08 | -$0.11–-$0.05 | +20.3% | $9.8M |
| Next Q | -$0.10 | -$0.13–-$0.05 | +21.8% | $5.1M |
| Current FY | -$0.39 | -$0.51–-$0.33 | +0.7% | $22.0M |
| Next FY | -$0.50 | -$1.04–-$0.17 | -5.4% | $26.1M |
Short side
FINRA· Oct 30, 2026SecBot reports
6 filings · 4 press releases · 0 bullish · 1 bearish · 1 mixed · 4 neutral- NEUTRAL SC 13GNov 10, 2026
State Street Corp filed a Schedule 13G disclosing a passive 4.1% stake in CytomX Therapeutics as…
State Street's stake is below the 5% threshold, so no further 13G amendments are required unless it crosses back above 5%. Monitor for any future 13D conversion or material changes in institutional…
- BEARISH PRESS-RELEASENov 5, 2026
CytomX reported Q3 2026 revenue of $1.7M, down from $6.0M a year ago due to the completion of the…
Monitor the January 2027 Varseta-M Phase 1 data update for dose selection and registrational strategy clarity; the cash runway into H2 2028 provides a long development horizon but the lack of…
- NEUTRAL 8-KNov 5, 2026
Revenue decline reflects completion of the Astellas collaboration performance obligation. The…
The earnings were in line with consensus, but the revenue decline and widening loss underscore the pre-revenue stage. The key catalyst is the Varseta-M data update in January 2027, which will inform…
- NEUTRAL SC 13G/AOct 28, 2026
Bank of America Corp filed an amended Schedule 13G for CytomX Therapeutics, disclosing a passive…
Monitor for any future conversion to Schedule 13D if BofA's intent changes, but the passive certification and small incremental increase suggest routine portfolio management. No immediate trading…
All CTMX filing & press-release reports (10)
- SC 13G reportNov 10, 2026
- PRESS-RELEASE reportNov 5, 2026
- 8-K reportNov 5, 2026
- SC 13G/A reportOct 28, 2026
- INST-CLUSTER reportSep 22, 2026
- 8-K reportJun 22, 2026
- PRESS-RELEASE reportMar 17, 2026
- PRESS-RELEASE reportMar 16, 2026
- PRESS-RELEASE reportMar 16, 2026
- PRESS-RELEASE reportMar 4, 2026